Eiger BioPharmaceuticals, Inc. (EIGR)

NASDAQ: EIGR · IEX Real-Time Price · USD
9.29
+0.60 (6.90%)
Aug 10, 2022 4:00 PM EDT - Market closed

Company Description

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally.

Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection.

The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia.

Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.

Eiger BioPharmaceuticals, Inc.
Eiger BioPharmaceuticals Logo
Country United States
Industry Biotechnology
Sector Health Care
Employees 51
CEO Krisztina Zsebo

Contact Details

Address:
2155 Park Blvd
Palo Alto, California 94306-1543
United States
Phone 650 272 6138
Website eigerbio.com

Stock Details

Ticker Symbol EIGR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 0001305253
CUSIP Number 15117E107
ISIN Number US28249U1051
Employer ID 33-0971591
SIC Code 2836

Key Executives

Name Position
David A. Cory M.B.A., MBA, R.Ph, R.Ph. Business Founder, President, Chief Executive Officer and Director
Dr. Jeffrey S. Glenn M.D., Ph.D. Scientific Founder and Independent Director
Sriram Ryali M.B.A. Chief Financial Officer
Eldon C. Mayer III, M.B.A. Executive Vice President and Chief Commercial Officer
Christopher A. Kurtz Chief Technical Officer
Erik Atkisson General Counsel, Corporate Secretary and Chief Compliance Officer
Dr. Ingrid C. Choong Senior Vice President of Clinical Development
Dr. Stephana E. Patton J.D., Ph.D. Consultant
Rich Franco M.B.A. Senior Vice President of Regulatory Affairs
Dr. Colin Hislop M.D. Senior Vice President of Clinical and Development Operations

Latest SEC Filings

Date Type Title
Aug 4, 2022 10-Q Quarterly report [Sections 13 or 15(d)]
Aug 4, 2022 8-K Current report
Jul 19, 2022 4 Statement of changes in beneficial ownership of securities
Jul 19, 2022 3 Initial statement of beneficial ownership of securities
Jul 18, 2022 8-K Current report
Jun 21, 2022 8-K Current report
Jun 7, 2022 8-K Current report
May 11, 2022 SC 13G/A Statement of acquisition of beneficial ownership by individuals
May 5, 2022 10-Q Quarterly report [Sections 13 or 15(d)]
May 5, 2022 8-K Current report